Heterologous resistance in Schistosomiasis

Hillyer, George V.

doi:10.1590/s0074-02761987000800029

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune cross-reaction among helminths and crossprotection between schistosome and fasciola have been previously reported (7)(8)(9). Recombinant FABP, r-Sm14, induces high levels of protection against S. mansoni infection in two outbred animal models (Swiss mice − 65% and New Zealand rabbits − 90%), and immune crossprotection against infection by F. hepatica in Swiss outbred mice (100%) (10,11).…”

Section: Research Notementioning

confidence: 94%

Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14

Almeida

Torloni²,

Lee‐Ho

et al. 2003

Parasite Immunology

View full text Add to dashboard Cite

Fasciola hepatica is the causative agent of fasciolosis in many areas in America, Europe, Africa, Asia and Australia. There is an urgent need for improved methods to control the parasite's transmission. We describe the use of an experimental vaccine based on a recombinant antigen cloned from another parasite, Schistosoma mansoni (Sm14), that induces high levels of cross protection in mice against both S. mansoni and F. hepatica. Sheep and mice vaccinated with Sm14 were significantly protected against challenge infection with metacercariae of Fasciola hepatica and were completely free of the histopathological hepatic damage related to liver fluke infection. The vaccine will provide a valuable new tool to aid in transmission control of this economically important disease.

show abstract

Section: Research Notementioning

confidence: 94%

Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14

Almeida

Torloni²,

Lee‐Ho

et al. 2003

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…The antigen in the Fh/SmIII(M) fraction that was protective against murine schistosomiasis mansoni (up to 77% reduction in mice) was identified as a 12 kDa protein and was denoted Fh12 (Hillyer, 1987;Hillyer et al, 1988a,b). Using a mono-specific, polyclonal antiserum to Fh12, a cDNA from an adult F. hepatica cDNA expression library was isolated that predicted a 14.7 kDa recombinant protein (denoted rFh15, see below) with high similarity to a family of FABPs (Rodriguez-Perez et al, 1992;Hillyer, 1995), including significant homology to a 14.8 S. mansoni FABP (rSm14, in Moser et al, 1991).…”

Section: Fatty Acid Binding Proteinsmentioning

confidence: 99%

Fasciola antigens as vaccines against fascioliasis and schistosomiasis

Hillyer

2005

J. Helminthol.

View full text Add to dashboard Cite

Fascioliasis is an important trematode infection of herbivores worldwide with increasing evidence of prevalence as a disease of humans. Vaccination studies with purified native and recombinant Fasciola antigens suggest that this approach to diminished morbidity and mortality and reduced transmission is a realistic goal. Among the major potential vaccine candidates are fatty acid binding protein (FABP), cysteine (cathepsin) proteases, haemoglobulin, leucine aminopeptidase, and a saposin-like protein. In the case of Fasciola hepatica FABP, cross-reaction and cross-protection against Schistosoma mansoni is an important feature. In addition to protective effects with significant worm burden reductions, some vaccine candidates also have anti-fecundity (smaller flukes), anti-pathology (less liver lesions), and anti-embryonation effects. Optimism is tempered by the fact that fascioliasis in humans is an orphan disease and in need of governmental and foundation support.

show abstract